We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cytogen has announced that researchers at a leading medical institution have
initiated a new clinical trial to evaluate the use of Quadramet in combination
with bisphosphonates for the treatment of pain associated with metastatic
bone disease in patients with recurrent or refractory multiple myeloma.
Human Genome Sciences has received clearance from the FDA for its investigational
new drug application to begin clinical trials of CCR5 mAb for the treatment
of HIV/AIDS.
Dyax has announced positive interim results from its Phase II, open-label, dose-ranging,
repeat-dosing clinical trial of DX-88 in hereditary angioedema (HAE), referred
to as EDEMA2 (Evaluating DX-88's Effects on Mitigating Angioedema).
The Immune Response has completed two Phase II clinical trials, one in Italy
and one in Spain, investigating its lead HIV immune-based therapeutic Remune
in HIV-positive subjects.
Sangamo BioSciences has submitted an investigational new drug application to
the FDA for SB-509, a novel therapeutic designed to protect and stimulate the
regeneration of peripheral nerve function in diabetics suffering from peripheral
neuropathy.
The FDA has issued an "approvable letter" for Schering's drug Bonefos,
which is intended to reduce the occurrence of bone cancer in patients who have
had breast cancer surgery.
Lexicon Genetics has advanced two of its drug discovery programs into preclinical
development in preparation for investigational new drug applications.
Nabi Biopharmaceuticals has announced encouraging results from its U.S. Phase
I/II clinical trial using Altastaph [Staphylococcus aureus Immune Globulin
Intravenous (Human)] to treat adult in-hospital patients with persistent Staphylococcus
aureus (S. aureus) bloodstream infections (bacteremia).